Marianne Wilson, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1255728010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,526, more than ten times the $14 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MS, where the typical reported total is $4,678.
Across 158 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$574
- Abbott$380
- Amgen$333
- Medtronic$252
- Boehringer Ingelheim$206
- BETA Bionics, Inc.$188
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,27596%
- Education$1264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $574 |
| Abbott | 19 | $380 |
| Amgen | 19 | $333 |
| Medtronic(2 entities) | 4 | $252 |
| Boehringer Ingelheim | 12 | $206 |
| BETA Bionics, Inc. | 9 | $188 |
| Xeris Pharmaceuticals, Inc. | 5 | $177 |
| Bayer | 4 | $161 |
| AbbVie | 8 | $132 |
| Radius Health, Inc. | 4 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $119 |
| Novo Nordisk | 6 | $100 |
| Chiasma, Inc. | 1 | $97 |
| Novartis | 4 | $77 |
| Corcept Therapeutics | 3 | $64 |
| AstraZeneca | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Madrigal Pharmaceuticals | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Cequr Corporation | 1 | $33 |
| Merck | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Halozyme Inc | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
How this compares
$3,401 in reported general payments places this provider in the 40th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $291,015 |
| JardianceEmpagliflozin | 161 | $181,135 |
| MounjaroTirzepatide | 107 | $148,517 |
| TrulicityDulaglutide | 72 | $108,613 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 99 | $103,771 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $50,039 |
| JanuviaSitagliptin Phosphate | 61 | $44,508 |
| FarxigaDapagliflozin Propanediol | 41 | $39,815 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 59 | $37,240 |
| Tresiba Flextouch U-100Insulin Degludec | 85 | $37,000 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $35,550 |
| RybelsusSemaglutide | 14 | $25,918 |
| TradjentaLinagliptin | 20 | $22,760 |
| ProliaDenosumab | 13 | $21,822 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 19 | $16,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $100 | $337,299258 claims |
| Lilly USA, LLCMounjaro, Trulicity | $574 | $257,129179 claims |
| Boehringer IngelheimJardiance, Tradjenta | $206 | $203,895181 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $119 | $103,77199 claims |
| MerckJanuvia | $27 | $44,50861 claims |
| AstraZenecaFarxiga | $61 | $39,81541 claims |
| AmgenProlia | $333 | $21,82213 claims |
| AbbVieSynthroid | $132 | $3,33149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Amanda SchieferJackson$204K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.